PREVENE : Preemptive therapy with Venetoclax for high risk CLL stage A patients, a phase II trial of the FILO

2024-513718-37-00 Protocol FILOCLL10-PREVENE Therapeutic exploratory (Phase II) Ongoing, recruitment ended

Start 1 Aug 2024 · Status Ongoing, recruitment ended · 1 EU/EEA countries · 20 sites · Protocol FILOCLL10-PREVENE

Overview

Sponsor-declared trial summary

Phase Therapeutic exploratory (Phase II)
Status Ongoing, recruitment ended
Participants planned 45
Countries 1
Sites 20

IGHV unmutated patients with high-risk stage A CLL features.

Key facts

Sponsor
French Innovative Leukemia Organization
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Hemic and Lymphatic Diseases [C15]
Trial duration
1 Aug 2024 → ongoing
Decision date (initial)
2024-08-01
Transition trial
Yes
Low-intervention
No
Rare-disease indication
Yes
Vulnerable population
No

External identifiers

EU CT number
2024-513718-37-00
EudraCT number
2018-001475-20
ClinicalTrials.gov
NCT03766763

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

IGHV unmutated patients with high-risk stage A CLL features.

VersionLevelCodeTermSystem organ class
21.1 LLT 10008993 Chronic lymphoid leukaemia 10029104
21.1 LLT 10025302 Lymphoid leukaemia chronic 10029104

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

French Innovative Leukemia Organization

Sponsor organisation
French Innovative Leukemia Organization
Address
2 Boulevard Tonnelle
City
Tours
Postcode
37000
Country
France

Scientific contact point

Organisation
French Innovative Leukemia Organization
Contact name
Pr Vincent LEVY

Public contact point

Organisation
French Innovative Leukemia Organization
Contact name
Pr Vincent LEVY

Locations

1 EU/EEA country · 20 investigational sites

By country

CountryMS statusPlanned subjectsSites
France Ongoing, recruitment ended 45 20
Rest of world 0

Investigational sites

France

20 sites · Ongoing, recruitment ended
Centre Hospitalier De Versailles
hematologie, 177 Rue De Versailles, Le Chesnay, Le Chesnay Rocquencourt
Centre Hospitalier Departemental Vendee
hematologie, Boulevard Stephane Moreau, 85925, La Roche Sur Yon Cedex 9
Centre Hospitalier Universitaire De Saint Etienne
hematologie, Avenue Albert Raimond, 42270, Saint Priest En Jarez
Centre Henri Becquerel
hematologie, 1 Rue D Amiens, 76000, Rouen
Centre Hospitalier Universitaire De Nantes
hematologie, 1 Place Alexis Ricordeau, 44000, Nantes
CHU Henri Mondor
hematologie, 51 avenue du marechal de Lattre de Tassigny, 94000, creteil
CHU Reunion site sur
hematologie, BP 350, France, Saint Pierre
Centre Hospitalier De Beziers
hematologie, Zone Dactivite Montimaran, 2 Rue Valentin Hauy, Beziers
Institut Paoli Calmettes
hematologie, 232 Boulevard De Sainte Marguerite, Bp 156, Marseille
Centre Hospitalier Universitaire Amiens Picardie
hematologie, 30 Avenue De La Croix Jourdain, 80054, Amiens Cedex 1
Centre Hospitalier Universitaire D'Angers
maladie du sang, 4 Rue Larrey, 49100, Angers
Centre Hospitalier Le Mans
hematologie, 194 Avenue Rubillard, 72037, Le Mans Cedex 9
Hospices Civils De Lyon
hematologie, 165 Chemin Du Grand Revoyet, 69310, Pierre Benite
Centre Hospitalier Universitaire Grenoble Alpes
hematologie, Boulevard De La Chantourne, Cs 10217, Grenoble Cedex 9
CHRU Tours Hopital Bretonneau
hematologie, 2 Tonnelle boulevard, 37000, Tours
Centre Leon Berard
hematologie, 28 Rue Laennec, 69008, Lyon
Centre Hospitalier Universitaire D Orleans
hematologie, 14 Avenue De L Hopital, Cs 86709, Orleans Cedex 2
Hôpital Avicenne
hematologie, 125 rue de Stalingrad, 93000, Bobigny
Hopital Prive Sevigne
hematologie, 3 Rue Du Chene Germain, 35510, Cesson Sevigne
Centre Hospitalier De Perpignan
hematologie, 20 Avenue Du Languedoc, Cs 49954, Perpignan Cedex

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
France 2024-08-01 2024-08-01 2024-08-02

Application history

2 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-07-22 France Acceptable
2024-07-29
2024-08-01
2 NON SUBSTANTIAL MODIFICATION NSM-1 2025-03-06 France Acceptable
2024-07-29
2025-03-06